AML (Artificial Markup Language) organ-like model and construction method thereof

Through microfluidic control and 3D bioprinting technology, AML organoid model is constructed to simulate the microenvironment of AML tumors, and the problem of poor efficacy of traditional treatment plans for AML patients is solved, individualized drug screening and diagnosis is realized, and AML patients are provided with More accurate treatment options.

CN119060848AActive Publication Date: 2024-12-03SICHUAN FARSOON TURING ADDITIVE MFG TECH CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411335205.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2024-12-03
Estimated Expiration
2044-09-24

AI Technical Summary

Technical Problem

The high heterogeneity of AML patients leads to poor efficacy of traditional treatment plans, and some patients cannot tolerate intensive treatment and recurrence of disease. The existing technology is difficult to effectively simulate the tumor microenvironment, affecting drug screening and personalized treatment.

Method used

Microfluidic control and 3D bioprinting technology are used to construct the AML organoid model, and the nutrient circulation mechanism, tumor cell growth mechanism, external cell stimulation mechanism and endothelial cell growth mechanism are constructed from top to bottom, using core/shell GelMA-TGF- β1/gelatin ink system simulates the microenvironmental conditions of tumor cells, including key factors such as oxygen concentration, nutrient supply and pH.

Benefits of technology

Accurate simulation of the AML tumor microenvironment is achieved, providing an individualized drug screening and diagnostic basis, providing a more realistic research and diagnostic basis for the treatment of AML patients, and improving the accuracy and reliability of drug screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060848A_ABST
    Figure CN119060848A_ABST
Patent Text Reader

Abstract

The invention discloses an AML organ-like model and a construction method thereof, and relates to the technical field of micro-fluidic chips. The invention comprises an AML (acute myeloid leukemia) type organ model which is formed by 3D (three-dimensional) biological printing and sequentially comprises a nutrition circulation mechanism, a tumor cell growth mechanism, an extracellular stimulation mechanism and an endothelial cell growth mechanism from top to bottom, a first flow channel is formed in the nutrition circulation mechanism, and a first test electrode is mounted in the first flow channel; a second flow channel is formed in the tumor cell growth mechanism, channel ink is filled in the second flow channel, and a second test electrode is mounted in the second flow channel; a cavity and an air supply channel which are communicated with each other are formed in the cell external stimulation mechanism, and the air supply channel is communicated with the cavity; a third flow channel is formed in the endothelial cell growth mechanism, and the inner wall of the third flow channel is filled with outer-layer ink; the purpose of constructing a high-flux drug sensitivity detection platform based on AML organs by utilizing the microfluidic and 3D biological printing technology aiming at the highly heterogeneous blood tumor such as AML is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of microfluidic chips, in particular to an AML organoid model and a construction method thereof. Background Art

[0002] Acute myeloid leukemia (AML) is a clonal blood malignancy derived from hematopoietic stem cells. AML is the most common form of leukemia in adults, accounting for about one-third of all leukemias worldwide. The incidence of AML is generally reported to be 3-5 per 100,000 people per year. There are 85,000 new cases of AML in China each year, with a 5-year survival rate of less than 20%. With the increase in life expectancy and the aging of the population in China, the incidence of AML is likely to increase significantly. The survival rate of AML patients is the lowest among all leukemias. Only 1 / 4 of adult AML patients survive more than 5 years after diagnosis. Moreover, in the past 20 years, the treatment of AML has progressed slowly and the survival rate has not improved significantly.

[0003] Currently, the traditional treatment for AML patients mainly adopts the "3+7" chemotherapy regimen, which combines anthracyclines such as idarubicin (IDA), daunorubicin (DNR), and mitoxantrone (MIT) with standard doses of Ara-C. In addition, the CAG regimen (cytarabine + aclarubicin + granulocyte colony-stimulating factor) and the HAG regimen (homoharringtonine + cytarabine + granulocyte colony-stimulating factor) are also widely used as low-intensity chemotherapy regimens. However, according to many previous studies, the overall efficacy of traditional treatment regimens in AML patients is not ideal, showing a lower remission rate and a shorter median overall survival (OS).

[0004] This phenomenon is mainly attributed to the high heterogeneity of AML patients, their poor prognosis, and the inability of some patients to tolerate intensive treatment, as well as the refractory nature of the disease. The fundamental reason is that AML cells themselves have extremely strong tumor heterogeneity, and the presence of multiple gene mutations causes tumor cells to undergo clonal evolution and form different subclones. At the same time, the heterogeneity of the tumor microenvironment, such as differences in blood vessels and oxygen supply, and differences in immune cells, also has an important impact on the patient's drug resistance. These different mutations, epigenetic variations, or downstream abnormalities may cause patients to present similar clinical manifestations, but trigger different treatment responses, ultimately leading to poor treatment effects. Summary of the invention

[0005] The purpose of the present invention is to provide an AML organoid model and a construction method thereof, so as to achieve the purpose of constructing a high-throughput drug sensitivity detection platform based on AML organoids by using microfluidics and 3D bioprinting technology for AML, a highly heterogeneous blood tumor.

[0006] In order to achieve the above object, the present invention adopts the following technical means: An AML organoid model, formed by 3D bioprinting, is constructed from top to bottom with a nutrient circulation mechanism, a tumor cell growth mechanism, a cell external stimulation mechanism, and an endothelial cell growth mechanism; A first flow channel is constructed in the nutrient circulation mechanism, and a first testing electrode is installed in the first flow channel; A second flow channel is constructed in the tumor cell growth mechanism, the second flow channel is filled with channel ink, and a second test electrode is installed in the second flow channel; The external cell stimulation mechanism is internally structured with a cavity and an air supply channel that are interconnected, and the air supply channel is connected to the cavity; A third flow channel is constructed in the endothelial cell growth mechanism, and the inner wall of the third flow channel is filled with an outer layer of ink.

[0007] Preferably, the nutrition circulation mechanism, tumor cell growth mechanism, cell external stimulation mechanism and endothelial cell growth mechanism are all formed by core / shell type GelMA-TGF-β1 / gelatin ink system as profiles; The profile is formed by a coaxial nozzle, including a tissue cell-carrying ink for an outer nozzle and an endothelial cell-carrying sacrificial ink for an inner nozzle.

[0008] Furthermore, the channel ink is prepared in the following manner: A1. Add the pig skin gelatin into the PBS solution at a concentration of 15% and stir in a 50°C water bath for 30 minutes until it is completely dissolved. A2. Slowly add methyl acrylate (MA) to the gelatin solution, keep the temperature at 37°C, until the MA concentration in the gelatin solution reaches 6%, and take it out after two hours of reaction to obtain GelMA; A3. GelMA was dialyzed in deionized water for one week, and after freeze-drying, 5 g of TGF-β1 monomer was dissolved in 15% GelMA with PBS and stirred for 5 minutes to obtain GelMA-TGF-β1; A4. Mix GelMA-TGF-β1 and KG-1a cells to obtain the channel ink.

[0009] Furthermore, the outer layer ink is prepared in the following manner: B1. Adipose-derived mesenchymal stem cells were extracted from 4-week-old rats; B2. Culture with complete mesenchymal stem cell medium, change the medium every two days, and subculture when the cell confluence reaches 80%-90%. Cells after two subcultures are used for organoid culture; B3. Every 105 mesenchymal stem cells (MSCs) are mixed with 1 ml of 5% sodium alginate in equal proportions to prepare the channel ink.

[0010] Furthermore, the nutrient circulation mechanism, tumor cell growth mechanism, cell external stimulation mechanism and endothelial cell growth mechanism are stacked in sequence from top to bottom, and a one-way filter membrane is constructed between two adjacent layers.

[0011] Furthermore, the nutrient circulation mechanism is constructed with a vertically penetrating electrode mounting hole, which passes through the first flow channel and extends into the second flow channel. A measuring electrode is installed in the electrode mounting hole, and the part of the measuring electrode located in the first flow channel serves as the first test electrode, and the part of the measuring electrode located in the second flow channel serves as the second test electrode.

[0012] Furthermore, the measuring electrodes include a reference electrode, an enzyme sensor and a counter electrode in sequence along the flow direction of the liquid in the first flow channel.

[0013] Furthermore, the liquid inlet end and the liquid outlet end of the first flow channel are respectively constructed on the opposite side walls of the nutrient circulation mechanism, the ink inlet end and the ink outlet end of the third flow channel are respectively constructed on the opposite side walls of the endothelial cell growth mechanism, and the orthographic projection of the first flow channel on the endothelial cell growth mechanism coincides with that of the third flow channel.

[0014] Furthermore, the ink inlet and ink outlet of the second flow channel are respectively constructed on opposite sides of the tumor cell growth mechanism, and the second flow channel includes a main flow channel and a measuring flow channel separately connected to each second test electrode, and a dry film blocking layer is arranged on the upstream side of the measuring flow channel relative to the second test electrode, and the two ends of the main flow channel serve as the ink inlet and ink outlet, and the main flow channel is also connected to a test channel, and the test channel extends from the side wall of the tumor cell growth mechanism and is connected to a nano nozzle.

[0015] At the same time, a method for constructing the aforementioned AML organoid model comprises the following steps: S1. Configure channel ink and outer ink; S2. forming the endothelial cell growth mechanism by 3D printing, introducing the outer layer of ink into the third flow channel, and curing it by ultraviolet light; S3. Forming the cell external stimulation mechanism above the endothelial cell growth mechanism using 3D printing, and curing using ultraviolet light; S4. forming the tumor cell growth mechanism above the cell external stimulation mechanism by 3D printing, and introducing the channel ink into the second flow channel, and curing it by ultraviolet light; S5. Forming the nutrient circulation mechanism above the tumor cell growth mechanism using 3D printing; S6. Insert electrodes to form the first test electrode and the second test electrode.

[0016] During use, the present invention has the following beneficial effects: By combining microfluidics and 3D bioprinting technology, AML organoid models are prepared to simulate tumor heterogeneity. By constructing an environment that can accurately reproduce the tumor microenvironment to simulate a more realistic environment, the response of individual patients to therapy can be predicted, providing a research and diagnostic basis for drug screening and personalized treatment.

[0017] The model is also built using specific biological ink to ensure the accuracy and reliability of the simulated environment.

[0018] It can accurately reproduce the microenvironment conditions of tumor cells, including key factors such as oxygen concentration, nutrient supply, and pH, and effectively simulate the complex interactions between tumor cells and various cells in the surrounding microenvironment. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Schematic diagram of the structure of the AML organoid model of the present invention.

[0020] Figure 2 for Figure 1 Schematic diagram of the explosion structure.

[0021] Figure 3 It is a schematic diagram of the cross-sectional structure of the tumor cell growth mechanism of the present invention.

[0022] Figure 4 This is a schematic diagram of the first flow channel layout structure of the present invention.

[0023] Among them, 1-nutrient circulation mechanism, 2-tumor cell growth mechanism, 3-cell external stimulation mechanism, 4-endothelial cell growth mechanism, 5-first flow channel, 6-second flow channel, 7-cavity, 8-air supply channel, 9-third flow channel, 10-electrode mounting hole, 11-main flow channel, 12-measurement flow channel, 13-dry film blocking layer, 14-test channel, 15-nano nozzle. DETAILED DESCRIPTION

[0024] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Generally, the components of the embodiments of the present invention described and shown in the drawings here can be arranged and designed in various different configurations.

[0025] Therefore, the following detailed description of the embodiments of the present invention provided in the accompanying drawings is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0026] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features of the embodiments may be combined with each other.

[0027] It should be noted that similar reference numerals and letters denote similar items in the following drawings, and therefore, once an item is defined in one drawing, further definition and explanation thereof is not required in subsequent drawings.

[0028] In the description of the present invention, it should be noted that the terms "center", "up", "down", "left", "right", "vertical", "horizontal", "inside", "outside", etc. indicate positions or positional relationships based on the positions or positional relationships shown in the accompanying drawings, or the positions or positional relationships in which the invented product is usually placed when in use, or the positions or positional relationships commonly understood by those skilled in the art, which are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first", "second", etc. are only used to distinguish the description, and cannot be understood as indicating or implying relative importance.

[0029] In the description of the present invention, it is also necessary to explain that, unless otherwise clearly specified and limited, the terms "set", "install", "connect", and "connect" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two elements. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0030] Please refer to Figures 1 to 4As shown, an AML organoid model is formed by 3D bioprinting, and is sequentially constructed from top to bottom with a nutrient circulation mechanism 1, a tumor cell growth mechanism 2, a cell external stimulation mechanism 3, and an endothelial cell growth mechanism 4; The nutrient circulation mechanism 1 is used for exchanging nutrients. Specifically, a first flow channel 5 is constructed in the nutrient circulation mechanism 1, and a first test electrode is installed in the first flow channel 5; Nutrients circulate in the first flow channel 5, and gradually penetrate downward to the tumor cell growth mechanism 2, the cell external stimulation mechanism 3 and the endothelial cell growth mechanism 4. The aforementioned first test electrode is used to test the parameters of the products generated by the tumor cells.

[0031] A second flow channel 6 is constructed in the tumor cell growth mechanism 2, the second flow channel 6 is filled with channel ink, and a second test electrode is installed in the second flow channel 6; The aforementioned tumor cell growth mechanism 2 is used to inoculate tumor cells for growth and provide a growth environment for the tumor cells.

[0032] The external cell stimulation mechanism 3 is internally constructed with a cavity 7 and an air supply channel 8 that are interconnected, and the air supply channel 8 is connected to the cavity 7; The air supply channel 8 of the aforementioned external cell stimulation mechanism 3 is connected to an external air pump. Under the action of the air pump, gas is regularly pumped out to apply negative pressure toward the cavity 7, driving the stretching of the cavity 7, thereby simulating the heart beating environment and providing external stimulation to the aforementioned inoculated cells.

[0033] A third flow channel 9 is constructed in the endothelial cell growth mechanism 4 , and the inner wall of the third flow channel 9 is filled with an outer layer of ink.

[0034] The endothelial cell growth mechanism 4 is used to simulate the in vivo endothelial cell growth environment. Moreover, the cells in the endothelial cell growth mechanism 4 and the tumor cell growth mechanism 2 are inoculated before the entire system is started. During the operation of the system, only the nutrient circulation mechanism 1 located at the top layer has the inflow and outflow of culture fluid for nutrient supply.

[0035] Furthermore, the nutrition circulation mechanism 1, the tumor cell growth mechanism 2, the cell external stimulation mechanism 3 and the endothelial cell growth mechanism 4 are all formed using a core / shell type GelMA-TGF-β1 / gelatin ink system as a profile; The profile is formed by a coaxial nozzle, including a tissue cell-carrying ink for an outer nozzle and an endothelial cell-carrying sacrificial ink for an inner nozzle.

[0036] Specifically, a core / shell GelMA-TGF-β1 / gelatin ink system was used, and the coaxial nozzle technology was used to achieve the simultaneous release of tissue cell ink (external nozzle) and endothelial cell sacrificial ink (inner nozzle). During the printing process, the sacrificial ink serves as a supporting structure to ensure the formation of the flow channel; in the subsequent culture stage, the sacrificial ink will gradually melt to form a smooth flow channel network. At the same time, endothelial cells will be released from the sacrificial ink and tightly adhere to the inner wall of the flow channel to achieve the vascularization process. This process effectively simulates the natural transition from the flow channel network to the vascularized network, which is closer to the real environment in the body than traditional methods.

[0037] For the aforementioned channel ink, the channel ink is prepared in the following manner: A1. Add the pig skin gelatin into the PBS solution at a concentration of 15% and stir in a 50°C water bath for 30 minutes until it is completely dissolved. A2. Slowly add methyl acrylate (MA) to the gelatin solution, keep the temperature at 37°C, until the MA concentration in the gelatin solution reaches 6%, and take it out after two hours of reaction to obtain GelMA; A3. GelMA was dialyzed in deionized water for one week, and after freeze-drying, 5 g of TGF-β1 monomer was dissolved in 15% GelMA with PBS and stirred for 5 minutes to obtain GelMA-TGF-β1; A4. Mix GelMA-TGF-β1 and KG-1a cells to obtain the channel ink.

[0038] In addition, for the outer layer ink, the outer layer ink is prepared in the following manner: B1. Adipose-derived mesenchymal stem cells were extracted from 4-week-old rats; B2. Culture with complete mesenchymal stem cell medium, change the medium every two days, and subculture when the cell confluence reaches 80%-90%. Cells after two subcultures are used for organoid culture; B3. Every 105 mesenchymal stem cells (MSCs) are mixed with 1 ml of 5% sodium alginate in equal proportions to prepare the channel ink.

[0039] Furthermore, in order to allow the nutrients on the top layer to permeate downward in one direction better, the nutrient circulation mechanism 1, tumor cell growth mechanism 2, cell external stimulation mechanism 3 and endothelial cell growth mechanism 4 are stacked in sequence from top to bottom, and a one-way filter membrane is constructed between two adjacent layers.

[0040] In order to improve the integrity of the entire system, a vertically penetrating electrode mounting hole 10 is constructed on the nutrient circulation mechanism 1, and the electrode mounting hole 10 passes through the first flow channel 5 and extends into the second flow channel 6. A measuring electrode is installed in the electrode mounting hole 10, and the part of the measuring electrode located in the first flow channel 5 serves as the first test electrode, and the part of the measuring electrode located in the second flow channel 6 serves as the second test electrode.

[0041] Furthermore, the measuring electrodes include a reference electrode, an enzyme sensor and a counter electrode in sequence along the liquid flow direction in the first flow channel 5 .

[0042] At the same time, the liquid inlet end and the liquid outlet end of the first flow channel 5 are respectively constructed on the opposite side walls of the nutrient circulation mechanism 1, and the ink inlet end and the ink outlet end of the third flow channel 9 are respectively constructed on the opposite side walls of the endothelial cell growth mechanism 4, and the orthographic projection of the first flow channel 5 on the endothelial cell growth mechanism 4 coincides with that of the third flow channel 9.

[0043] In addition, since biological samples usually contain complex matrices and salts, these components will interfere with mass spectrometry analysis. Therefore, the ink inlet and ink outlet of the second flow channel 6 are respectively constructed on opposite sides of the tumor cell growth mechanism 2, and the second flow channel 6 includes a main flow channel 11 and a measurement flow channel 12 separately connected to each second test electrode. A dry film blocking layer 13 is provided on the upstream side of the measurement flow channel 12 relative to the second test electrode. The two ends of the main flow channel 11 serve as the ink inlet and ink outlet. The main flow channel 11 is also connected to a test channel 14, and the test channel 14 extends from the side wall of the tumor cell growth mechanism 2 and is connected to a nano nozzle 15.

[0044] In general, the organoid model described above is prepared in the following manner: S1. channel ink and outer layer ink are configured; S2. forming the endothelial cell growth mechanism 4 by 3D printing, and introducing the outer layer ink into the third flow channel 9, and curing it by ultraviolet light; S3. Forming the cell external stimulation mechanism 3 on the top of the endothelial cell growth mechanism 4 by 3D printing, and curing by ultraviolet light; S4. Forming the tumor cell growth mechanism 2 above the cell external stimulation mechanism 3 by 3D printing, and introducing the channel ink into the second flow channel 6, and curing it by ultraviolet light; S5. Forming the nutrient circulation mechanism 1 above the tumor cell growth mechanism 2 by 3D printing; S6. Insert electrodes to form the first test electrode and the second test electrode.

[0045] Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An AML organoid model, characterized in that The device is formed by 3D bioprinting and has a nutrient circulation mechanism (1), a tumor cell growth mechanism (2), a cell external stimulation mechanism (3), and an endothelial cell growth mechanism (4) from top to bottom. The nutrient circulation mechanism (1) is provided with a first flow channel (5), and a first testing electrode is installed in the first flow channel (5); A second flow channel (6) is constructed in the tumor cell growth mechanism (2), the second flow channel (6) is filled with channel ink, and a second test electrode is installed in the second flow channel (6); The external cell stimulation mechanism (3) is internally structured with a cavity (7) and an air supply channel (8) that are interconnected, and the air supply channel (8) is connected to the cavity (7); A third flow channel (9) is constructed in the endothelial cell growth mechanism (4), and the inner wall of the third flow channel (9) is filled with an outer layer of ink.

2. An AML organoid model according to claim 1, characterized in that The nutrient circulation mechanism (1), tumor cell growth mechanism (2), cell external stimulation mechanism (3) and endothelial cell growth mechanism (4) are all formed using a core / shell type GelMA-TGF-β1 / gelatin ink system as a profile; The profile is formed by a coaxial nozzle, including a tissue cell-carrying ink for an outer nozzle and an endothelial cell-carrying sacrificial ink for an inner nozzle.

3. An AML organoid model according to claim 1, characterized in that: The channel ink is prepared in the following manner: A1. Add the pig skin gelatin into the PBS solution at a concentration of 15% and stir in a 50°C water bath for 30 minutes until it is completely dissolved. A2. Slowly add methyl acrylate (MA) to the gelatin solution, keep the temperature at 37°C, until the MA concentration in the gelatin solution reaches 6%, and take it out after two hours of reaction to obtain GelMA; A3. GelMA was dialyzed in deionized water for one week, and after freeze-drying, 5 g of TGF-β1 monomer was dissolved in 15% GelMA with PBS and stirred for 5 minutes to obtain GelMA-TGF-β1; A4. Mix GelMA-TGF-β1 and KG-1a cells to obtain the channel ink.

4. An AML organoid model according to claim 1, characterized in that The outer layer ink is prepared in the following manner: B1. Adipose-derived mesenchymal stem cells were extracted from 4-week-old rats; B2. Culture with complete mesenchymal stem cell medium, change the medium every two days, and subculture when the cell confluence reaches 80%-90%. Cells after two subcultures are used for organoid culture; B3. Every 105 mesenchymal stem cells (MSCs) are mixed with 1 ml of 5% sodium alginate in equal proportions to prepare the channel ink.

5. The AML organoid model according to claim 1, characterized in that The nutrient circulation mechanism (1), the tumor cell growth mechanism (2), the cell external stimulation mechanism (3) and the endothelial cell growth mechanism (4) are stacked in sequence from top to bottom, and a one-way filter membrane is constructed between two adjacent layers.

6. The AML organoid model according to claim 1, characterized in that: The nutrient circulation mechanism (1) is provided with an electrode mounting hole (10) which passes vertically through the first flow channel (5) and extends into the second flow channel (6). A measuring electrode is mounted in the electrode mounting hole (10). The portion of the measuring electrode located in the first flow channel (5) serves as the first test electrode, and the portion of the measuring electrode located in the second flow channel (6) serves as the second test electrode.

7. An AML organoid model according to claim 6, characterized in that: The measuring electrodes include a reference electrode, an enzyme sensor and a counter electrode in sequence along the flow direction of the liquid in the first flow channel (5).

8. The AML organoid model according to claim 1, characterized in that: The liquid inlet end and the liquid outlet end of the first flow channel (5) are respectively constructed on the opposite side walls of the nutrient circulation mechanism (1), the ink inlet end and the ink outlet end of the third flow channel (9) are respectively constructed on the opposite side walls of the endothelial cell growth mechanism (4), and the orthographic projection of the first flow channel (5) on the endothelial cell growth mechanism (4) coincides with that of the third flow channel (9).

9. The AML organoid model according to claim 1, characterized in that: The ink inlet end and the ink outlet end of the second flow channel (6) are respectively constructed on opposite sides of the tumor cell growth mechanism (2). The second flow channel (6) comprises a main flow channel (11) and a measuring flow channel (12) which is individually connected to each second test electrode. A dry film blocking layer (13) is provided on the measuring flow channel (12) on the upstream side relative to the second test electrode. The two ends of the main flow channel (11) serve as the ink inlet end and the ink outlet end. The main flow channel (11) is also connected to a test channel (14). The test channel (14) extends from a side wall of the tumor cell growth mechanism (2) and is connected to a nano nozzle (15).

10. A method for constructing an AML organoid model according to any one of claims 1 to 9, characterized in that: The following steps are involved: S1. Configure channel ink and outer ink; S2. forming the endothelial cell growth mechanism (4) by 3D printing, and introducing the outer layer ink into the third flow channel (9), and curing it by ultraviolet light; S3. Forming the cell external stimulation mechanism (3) above the endothelial cell growth mechanism (4) by 3D printing, and curing by ultraviolet light; S4. forming the tumor cell growth mechanism (2) above the cell external stimulation mechanism (3) by 3D printing, and introducing the channel ink into the second flow channel (6), and curing it by ultraviolet light; S5. Forming the nutrient circulation mechanism (1) above the tumor cell growth mechanism (2) using 3D printing; S6. Insert electrodes to form the first test electrode and the second test electrode.

Citation Information

Patent Citations

  • Organ-like culture device for simulating bladder structure and application thereof

    CN115322904A

  • Osteosarcoma organ model, construction method and application

    CN115651909A

  • Tumor and vascular endothelial cell co-culture microfluidic system

    CN116836798A

  • Organ chip for constructing malignant tumor bone metastasis ecological niche, organ chip and application

    CN116875459A

  • Coaxial heterogeneity tumor model as well as preparation method and application thereof

    CN118652849A